[Interindividual pharmacokinetic variability in long-term antibiotherapy]
L Bourguignon1, S Goutelle, J Burdin de Saint Martin
1Université Lyon-1, UMR CNRS 5558, biométrie et biologie évolutive, bâtiment G.-Mendel, 43, boulevard du 11-Novembre-1918, 69622 Villeurbanne cedex, France. laurent.bourguignon@chu-lyon.fr
Objective:
The authors wanted to assess intraindividual pharmacokinetic variability, with a case of long-term amikacin therapy.
Design:
A 92-year-old female patient, weighing 44kg, with renal failure, was treated by amikacin for 52 days. Her individual pharmacokinetic parameters were assessed 12 times in the course of therapy. The intraindividual variability of key parameters was quantified and compared with published interindividual variability.
Results:
Intraindividual volume and clearance variability was measured at about one fourth to one third of the value observed for interindividual variability. Half-life intraindividual variability was almost equivalent to the interindividual variability: 24.5% versus 32%.
Conclusions:
The high pharmacokinetic variability observed has important potential clinical consequences. This case illustrates the need to ensure the effectiveness of treatment, to re-evaluate periodically the patient's status in order to take into account the intraindividual variability of pharmacokinetics parameters.
Related Concept Videos
Dosage Regimen: Individualization
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
Pharmacokinetics in Pediatric Patients: Drug Excretion
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Nonlinear Pharmacokinetics: Causes of Nonlinearity
Nonlinear drug absorption can occur when the process is rate-limited by solubility, carrier-mediated transport systems, or saturation of the presystemic gut wall or hepatic metabolism. For instance, high doses of riboflavin...


